Glowing drug reveals why lung cancer immunotherapy fails

NCT ID NCT07653438

Not yet recruiting Knowledge-focused Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests a new way to see where an immunotherapy drug goes in the lungs of people with stage III lung cancer. Twenty participants will receive a small dose of a fluorescent version of the drug durvalumab, then have a special camera bronchoscopy to spot the drug in tumors and lymph nodes. The goal is to understand why some patients stop responding to immunotherapy after chemoradiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab-680LT (a fluorescently labeled immunotherapy drug)
What this could lead to: If successful, this imaging method could help doctors predict which patients will benefit from immunotherapy, potentially personalizing treatment for stage III lung cancer.
What could go wrong: This is a very small early-phase study (20 people) focused on imaging, not treatment. The fluorescent signal may not reliably predict treatment response, and the approach may not be widely usable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE III NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STAGE III NON-SMALL CELL LUNG CANCER UNRESECTABLE STAGE III NSCLC

More trials for these conditions

Other studies related to the condition(s) this trial covers.